These drugs carry risks and may not help, but many dementia patients get them anyway

August 18, 2020

Nearly three-quarters of older adults with dementia have filled prescriptions for medicines that act on their brain and nervous system, but aren't designed for dementia, a new study shows.

That's despite the special risks that such drugs carry for older adults -- and the lack of evidence that they actually ease the dementia-related behavior problems that often prompt a doctor's prescription in patients with Alzheimer's disease and related disorders. In fact, some of the drugs have been linked to worse cognitive symptoms in old adults.

The study looks at several classes of psychoactive drugs, including ones that the federal government has actively encouraged nursing homes to limit using in residents with dementia. The new study suggests a need to reduce prescribing to people living at home with dementia, too.

In all, 73.5% of the study's community-based population filled at least one prescription for an antidepressant, opioid painkiller, epilepsy drug, anxiety medication or antipsychotic drug in a one-year period, according to Medicare prescription records.

The percentages generally were even higher among women, non-Hispanic white patients, people in their late 60s and early 70s, and people with low incomes.

The study is published in the journal JAMA and based on data from 737,839 people with dementia, and is the first large-scale study of prescription-filling patterns for psychoactive medications outside of nursing homes and other long-term care facilities.

Nearly half of those in the study received an antidepressant, which might be prescribed to try to counteract the withdrawal and apathy often seen in dementia, says lead author Donovan Maust, M.D., M.S., a geriatric psychiatrist at the University of Michigan and VA Ann Arbor Healthcare System. Unfortunately, antidepressants don't treat this aspect of dementia, he says.

Even so, the study shows antidepressant prescribing at nearly triple the rate for older adults overall.

Meanwhile, for each of the other drug types studied, nearly a quarter of the adults with dementia filled at least one prescription.

"As a nation we have a goal of keeping dementia patients living in the community as much as possible. But the use of these medications appears to be as high for them as it is for those who are in nursing homes," says Maust, who specializes in helping patients with dementia-related behavioral issues at Michigan Medicine, U-M's academic medical center. "Clinicians and caregivers may need more support to provide non-drug based approaches to prevent or address the symptoms that these medications are probably being prescribed for."

Known risks

None of the drug classes studied has received U.S. Food and Drug Administration approval for use in dementia, and Maust says that evidence for their off-label use is slim.

But all of the drugs are associated with special risks to people in their 60s and older, including falls or dependence that could lead to withdrawal. Most are included on the list known as the Beers criteria, which identifies medications with extra risks for all older adults, not just those with dementia.

While there is limited evidence that antidepressants help people with dementia, Maust notes that someone who had depression before they developed dementia might benefit from staying on a drug that worked for them in the past.

And while there is little evidence of benefit, all these medications have side effects. For example, some people starting a new antidepressant can experience nausea or feel a little "jittery." Unfortunately, a person with dementia might have difficulty articulating such side effects to the loved one who takes care of them. Instead, they may appear more agitated - leading to another prescription medication to calm them.

While the current study doesn't look at polypharmacy - the use of multiple psychoactive drugs by the same patient - Maust is exploring this issue further in the Medicare data.

The long haul

Maust notes that, of the 29% who received opioids, they most often filled just one or two short-term prescriptions, which may indicate treatment of an injury or acute pain.

But those receiving other drugs tended to fill multiple prescriptions in the year that Maust and his colleagues studied. This included epilepsy drugs that are sometimes prescribed as substitutes for antipsychotic drugs, or to treat chronic pain.

Taking these drugs for months on end is especially risky, says Maust. "A brain that has dementia is doing its best to function as well as it can," he explains. "If we add a psychotropic medication into the mix it may not be a helpful thing - and it comes with risks."

One bright spot in the data, Maust says, is that only one in five of the dementia patients studied had filled a prescription for an antipsychotic medicine such as Abilify, Seroquel or Risperdal. Because of the safety risks associated with antipsychotics, they have received a lot of regulatory attention and professional guidelines such as the "Choosing Wisely" for physicians urge caution.

On the other hand, this class of drugs has more evidence than the others that it actually helps some patients with behavioral problems such as aggression. "So it is worrisome that all the other classes -- which have less evidence of benefit -- are all prescribed more widely," says Maust.

Better education needed

In addition to helping caregivers and clinicians understand both the lack of evidence and the elevated risks that come with psychoactive medications, and to learn the non-drug caregiving strategies they can use to reduce behavioral issues in the person they're caring for, Maust notes they may just need better education about the disease itself.

Accessing support services through local, state and federal agencies, including Area Agency on Aging programs, and nonprofits such as the Alzheimer's Association and AARP, could help caregivers too, he says.

"Apathy and withdrawal, and a tendency to get agitated, are common symptoms of dementia," he says. "And as much as health care providers want to help these patients and their family caregivers, these medications are just not helpful enough to justify this amount of prescribing."
-end-
This research was supported by the National Institutes of Health's National Institute on Aging, grant R01AG056407. In addition to Maust, the study's authors are U-M's Julie Strominger, M.S., Julie Bynum, M.D., Kenneth Langa, M.D., Ph.D., Lauren Gerlach, D.O., M.S., Kara Zivin, Ph.D., and Steven Marcus, Ph.D., of the University of Pennsylvania. Maust, Langa and Zivin are members of the VA Center for Clinical Management Research; they and Bynum and Gerlach are members of the U-M Institute for Healthcare Policy and Innovation.

Michigan Medicine - University of Michigan

Related Science Articles from Brightsurf:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.

Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.

Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.

Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.

World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.

PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.

Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.

Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.

Read More: Science News and Science Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.